Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2017 / Cilt: 27 - Sayı: 2

The Endothelial Nitric Oxide Synthase Gene Variants as a Risk Factor for Chronic Lymphocytic Leukemia

Kronik Lenfositik Lösemide Risk Faktörü Olarak Endotelyal Nitrik Oksit Sentaz Gen Varyantlari

Pages
85–90
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our study suggest that the eNOS G894T variant may be associated with the development of CLL in the Turkish population

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Nitric oxide (NO) plays complicated roles in carcinogenesis.
📊
Key Findings & Data:The aim of this study was to determine whether eNOS variants (G894T and intron 4 VNTR a/b) affect in Chronic Lymphocytic Leukemia (CLL) risk in Turkish patients.
💡
Conclusion & Impact:Our study suggest that the eNOS G894T variant may be associated with the development of CLL in the Turkish population
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Nitric oxide (NO) plays complicated roles in carcinogenesis. Endothelial nitric oxide synthase (eNOS) gene is responsible for most of the NO produced. For this reason, it was considered that the eNOS gene variants is associated with cancer suspectibility. The aim of this study was to determine whether eNOS variants (G894T and intron 4 VNTR a/b) affect in Chronic Lymphocytic Leukemia (CLL) risk in Turkish patients. This is a prospective single-center crosssectional study in patients with CLL. A total of 60 CLL patients and 100 healthy controls with similar age and sex were included to this study. Two eNOS gene variants (G894T and intron 4VNTR a/b) were analysed with polymerase chain reaction (PCR) and/or restriction fragment length polymorphism (RFLP) methods. In this study, we found that the TT genotype of eNOS G894T variant was significantly associated with an increased risk in patient with CLL compared with control (OR: 0.867, Cl: 0.785-0.957, p= 0.001). There was not any significant difference in the eNOS G894T allele distribution between the groups (p> 0.05). In addition, no significant difference was detected between the CLL patients and healthy controls with respect to the frequencies of genotypes and alleles in intron 4 VNTR a/b variant of eNOS. eNOS gene variants (G894T and intron 4 VNTR a/b) in CLL patients were simultaneously analyzed for the first time in present study. Our study suggest that the eNOS G894T variant may be associated with the development of CLL in the Turkish population

Özet

Nitrik oksit (NO) karsinogenezde karışık role sahiptir. Endotelial nitrik oksit sentaz (eNOS) geni üretilen NO'un çoğundan sorumludur. Bu nedenle, eNOS gen varyantlarının kansere yatkınlık ile ilişkili olduğu varsayılmaktadır. Bu çalışmanın amacı kronik lenfositik lösemili (KLL) Türk hastalarında eNOS (G894T ve intron 4 VNTR a/b) varyantlarının risk faktörü olup olmadığı saptamaktır. Bu çalışma, KLL hastalarında prospektif, tek merkezli kesitsel bir çalışmadır. Bu çalışmanın amacı eNOS varyantlarının (C894T ve 4VNTR b/a) Türk hastalarda Kronik lenfositik lösemi (KLL) riskini etkileyip etkilemediğini saptamaktır. Bu çalışmaya 60 KLL hastası ve benzer yaş ve cinsiyette 100 sağlıklı kontrol dahil edilmiştir. İki eNOS gen varyantı (G894T ve intron 4VNTR a/b) polimeraz zincir reaksiyonu (PZR) ve/veya restriksiyon fragman uzunluk polimorfizmi (RFLP) yöntemleri ile analiz edildi. Bu çalışmada, eNOS G894T varyantı TT genotipinin KLL hastalarında kontrole göre belirgin şekilde artmış risk ile ilişkili olduğunu bulduk (OR: 0.867, Cl: 0.785-0.957, p= 0.001). eNOS G894T allel dağılımında gruplar arasında belirgin fark yoktu (p> 0.05). Ayrıca eNOS intron 4'deki VNTR a/b varyant genotip ve allel sıklığı açısından KLL hastaları ve kontroller arasında belirgin fark saptanmadı. Bu çalışmada KLL hastalarındaki eNOS gen varyantları (G894T ve intron 4VNTR a/b) ilk defa eş zamanlı olarak incelenmiştir. Sonuçlarımız eNOS G894T varyantının Türk toplumunda KLL gelişmesi ile ilişkili olabileceğini önermektedir

🔖

Cite This Article

PEHLİVAN, M., TOMATIR, A. G., NURSAL, A. F., SAHIN, H. H., PEHLİVAN, S. (2017). The Endothelial Nitric Oxide Synthase Gene Variants as a Risk Factor for Chronic Lymphocytic Leukemia. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 27 - Sayı: 2, 85–90. https://ajindex.com/articles/322789

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Hus I, Rolinski J. Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. Contemp Oncol (Pozn) 19: 361-367, 2015
  2. Landau DA, Wu CJ. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med 5: 47, 2013
  3. Vural F, Karaca E, Soyer N, et al. Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. UHOD 3: 179-184, 2014. 4 Haque S, Mandal RK, Akhter N, et al. G894T and 4a/b polymorphisms of NOS3 gene are not associated with cancer risk: a meta-analysis. Asian Pac J Cancer Prev 16: 2929-2937, 2015
  4. Yanar K, Çakatay U, Aydin S, et al. Relation between Endothelial Nitric Oxide Synthase Genotypes and Oxidative Stress Markers in Larynx Cancer. Oxid Med Cell Longev 2016: 4985063, 2016. 6 Albrecht EW, Stegeman CA, Heeringa P, et al. Protective role of endothelial nitric oxide synthase. Journal of Pathology 199: 8-17, 2003
  5. Polat F, Diler SB, Azazi I, Öden A. T-786C, G894T, and intron 4 VNTR (4a/b) polymorphisms of the endothelial nitric oxide synthase gene in bladdercancer cases. Asian Pac J Cancer Prev 16: 2199-2202, 2015
  6. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456, 2008
  7. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215, 1988
  8. Safarinejad MR, Safarinejad S, Shafiei N, Safarinejad S. Effects of the T-786C, G894T, and intron 4 VNTR (4a/b)polymorphisms of the endothelial nitric oxide synthase gene on the risk of prostate cancer. Urol Oncol 31: 1132-1140, 2013
  9. Routledge DJ, Bloor AJ. Recent advances in therapy of chronic lymphocytic leukaemia. Br J Haematol 174:351-367, 2016
  10. Rossi D, Gaidano G. The clinical implications of gene mutations in chronic lymphocytic leukaemia. Br J Cancer 114: 849- 854, 2016
  11. Lu J, Wei Q, Bondy ML, et al. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 107: 2245- 2253, 2006
  12. Chien YH, Bau DT, Jan KY. Nitric oxide inhibits DNA-adduct excision in nucleotide excision repair. Fre